Combined treatment of neurovegetative disorders in patients with ischemic heart disease with Long COVID-19 syndrome
Modern medical technology · 09.06.2026 · 18 (2) · 97-104
DOI: 10.14739/mmt.2026.2.342420 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern medical technology, online erschienen am 09.06.2026. Verfasst von N. S. Mykhailovska und 4 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The aim of the study. To assess the dynamics of neurovegetative disorders in patients with coronary artery disease (CAD) with Long COVID-19 syndrome under the influence of combined treatment with the inclusion of exogenous L-arginine and phenibut in basic therapy. Materials and methods. A prospective study with parallel distribution and elements of randomization included 31 patients with CAD: stable angina of exertion of functional class II–III (age 69.0 (64.0; 76.0) years)), who had suffered from moderate or severe COVID-19 coronavirus disease with manifestations of Long COVID-19 syndrome. Patients were divided into two groups depending on the prescribed treatment: group I (n = 15) – basic therapy for CAD was used; in group II (n = 16) a combination of L-arginine and phenibut was additionally prescribed against the background of basic therapy. Heart rate variability (HRV) parameters were assessed using 24-hour Holter ECG monitoring, degree of cognitive impairment – MoCa scale, anxiety-depressive – HADS scale, as well as their dynamics under the influence of the treatment.
Results
The use of combination therapy with the inclusion of exogenous L-arginine and phenibut in patients of group II contributed to an increase in the average integral indicator of cognitive status by 9.47 %, as well as a significant decrease in the level of anxiety-depressive symptoms: in the “Anxiety” subscale by 35.97 %, in the “Depression” subscale – by 20.81 % (p < 0.05). In the group receiving combination therapy with exogenous L-arginine and phenibut, a significant positive dynamics of most indicators of total HRV was determined: an increase in SDNNi by 1.22 times and 1.42 times, rMSSD, % by 1.56 times and 1.66 times, HRVT by 1.46 times and 1.40 in the daytime and nighttime periods, respectively. Analysis of HRV spectral indicators showed restoration of sympatho-parasympathetic balance and a significant decrease in the stress index by 1.89 and 2.03 times in the active and passive periods.
Conclusions
Adding exogenous L-arginine and phenibut to the basic therapy in patients with CAD who have had COVID-19 contributes to a significant reduction in anxiety and depressive symptoms, improvement of cognitive function, and stabilization of autonomic regulation of cardiac activity, which indicates a positive neuromodulatory effect of the combination therapy.
Zitieren
APA
Mykhailovska, N. S., Manuilov, S. M., Lisova, O. O., Shershnyova, O. V., & Hrytsai, H. V. (2026). Combined treatment of neurovegetative disorders in patients with ischemic heart disease with Long COVID-19 syndrome. Modern medical technology, 18(2), 97-104. https://doi.org/10.14739/mmt.2026.2.342420
Vancouver
Mykhailovska NS, Manuilov SM, Lisova OO, Shershnyova OV, Hrytsai HV. Combined treatment of neurovegetative disorders in patients with ischemic heart disease with Long COVID-19 syndrome. Modern medical technology. 2026;18(2):97-104. doi:10.14739/mmt.2026.2.342420
BibTeX
@article{Mykhailovska2026,
author = {Mykhailovska, N. S. and Manuilov, S. M. and Lisova, O. O. and Shershnyova, O. V. and Hrytsai, H. V.},
title = {Combined treatment of neurovegetative disorders in patients with ischemic heart disease with Long COVID-19 syndrome},
journal = {Modern medical technology},
year = {2026},
volume = {18},
number = {2},
pages = {97--104},
doi = {10.14739/mmt.2026.2.342420}
}
EUVIMED